Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidating Financial Statements - Additional Information (Details)

v3.23.1
Condensed Consolidating Financial Statements - Additional Information (Details)
Jan. 21, 2020
USD ($)
Debtinstrument
Mar. 31, 2023
USD ($)
Sep. 08, 2020
USD ($)
Iterum Therapeutics Bermuda Limited      
Condensed Financial Statements Captions [Line Items]      
Ownership percentage 100.00%    
Subsidiary Guarantors      
Condensed Financial Statements Captions [Line Items]      
Ownership percentage 100.00%    
2025 Exchangeable Notes      
Condensed Financial Statements Captions [Line Items]      
Aggregate principal amount   $ 12,607,000  
Private Placement | 2025 Exchangeable Notes      
Condensed Financial Statements Captions [Line Items]      
Aggregate principal amount $ 51,588,000    
Debt instrument price per unit 1,000    
Private Placement | RLNs      
Condensed Financial Statements Captions [Line Items]      
Aggregate principal amount $ 103,000    
Number of debt instruments within each notes | Debtinstrument 50    
Rights Offering | 2025 Exchangeable Notes      
Condensed Financial Statements Captions [Line Items]      
Aggregate principal amount     $ 220,000
Rights Offering | RLNs      
Condensed Financial Statements Captions [Line Items]      
Aggregate principal amount     $ 440